# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Jeffrey Silber maintains TrueBlue (NYSE:TBI) with a Outperform and raises the price target from $7 to $8.
TrueBlue (NYSE:TBI) sees Q3 sales of $400.000 million-$425.000 million vs $393.204 million analyst estimate.
TrueBlue (NYSE:TBI) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 28.5...
The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of TrueBlue ...
Proposal Significantly Undervalues the Company and Is Not in the Best Interest of ShareholdersShareholders Do Not Need to Take ...
Offers a Significant Premium of 61% to TrueBlue StockholdersHireQuest's High-Margin Franchising Model to drive near-term pr...